A RAS renaissance: emerging targeted therapies for KRAS-mutated non-small cell lung cancer.
about
Kirsten Ras* oncogene: Significance of its discovery in human cancer researchInducing Oncoprotein Degradation to Improve Targeted Cancer TherapyProtein Kinase Cι Drives a NOTCH3-dependent Stem-like Phenotype in Mutant KRAS Lung AdenocarcinomaSelective Targeting of CTNBB1-, KRAS- or MYC-Driven Cell Growth by Combinations of Existing DrugsClinicopathological and prognostic features of surgically resected pathological stage I lung adenocarcinoma harboring epidermal growth factor receptor and K-ras mutation.EGFR and K-Ras mutations in women with lung adenocarcinoma: implications for treatment strategy definition.KRAS driven expression signature has prognostic power superior to mutation status in non-small cell lung cancer.Targeting lung cancer through inhibition of checkpoint kinases.The Overexpression of FEN1 and RAD54B May Act as Independent Prognostic Factors of Lung Adenocarcinoma.Conditional robustness analysis for fragility discovery and target identification in biochemical networks and in cancer systems biology.KRAS mutant lung cancer: progress thus far on an elusive therapeutic target.RAS signaling and anti-RAS therapy: lessons learned from genetically engineered mouse models, human cancer cells, and patient-related studies.Clinical outcome of epidermal growth factor receptor-tyrosine kinase inhibitors therapy for patients with overlapping kirsten rat sarcoma 2 viral oncogene homolog and epidermal growth factor receptor gene mutationsKIAA1522 is a novel prognostic biomarker in patients with non-small cell lung cancer.Association Between Computed Tomographic Features and Kirsten Rat Sarcoma Viral Oncogene Mutations in Patients With Stage I Lung Adenocarcinoma and Their Prognostic Value.Farnesyl transferase inhibitor FTI-277 inhibits breast cell invasion and migration by blocking H-Ras activation.Epiregulin as a therapeutic target in non-small-cell lung cancerColorectal cancer-related mutant KRAS alleles function as positive regulators of autophagy.Selumetinib for the treatment of non-small cell lung cancer.Targeting the KRAS Pathway in Non-Small Cell Lung Cancer.Mutant KRAS and GNAS DNA Concentrations in Secretin-Stimulated Pancreatic Fluid Collected from the Pancreatic Duct and the Duodenal Lumen.Targeting prohibitins with chemical ligands inhibits KRAS-mediated lung tumours.Independent and core pathways in oncogenic KRAS signaling.Tissue of origin dictates branched-chain amino acid metabolism in mutant Kras-driven cancers.Identification of a New Potent Inhibitor Targeting KRAS in Non-small Cell Lung Cancer Cells.RAS oncogenes direct metastasis.Development of a Nucleotide Exchange Inhibitor That Impairs Ras Oncogenic Signaling.BET inhibition is an effective approach against KRAS-driven PDAC and NSCLC.Antitumor activity of sorafenib plus CDK4/6 inhibitor in pancreatic patient derived cell with KRAS mutationDiscovery of Inhibitors of Protein-Protein Interactions Using Fragment-Based Methods
P2860
Q26751212-913BD106-94FF-4658-99CB-E4B32D9DCC51Q26782145-2A969E43-539C-4DBC-A247-1BE21072BFC6Q28115044-2474491A-92A8-4B49-8526-97E4EE24CCAEQ28547522-A557C71D-5B75-4F83-9C4C-47125CC6561FQ33633715-03EA5E62-28A1-4861-8137-DF5DC73AA5D9Q34346624-D88CC3DC-0E96-44BD-BCA7-E64E3C8C01CAQ34544971-73AA5FB0-2673-4158-A84C-8C5958A78CC7Q35128547-28E9BAE9-8335-4036-81EF-0B44063FEC2CQ35797402-12E708BF-0C2E-4D1A-98C3-8F6C66FEA22DQ35813685-D50DCE4A-8D1D-4ACA-BB82-151A5EDB1891Q36369197-3ADADB6B-4660-4197-925B-7D97499A476CQ36398735-2519844E-DAD4-4E60-AC21-734AD583E750Q36477762-D07BD831-628C-4447-A20F-8B53AEF42670Q36819651-EF77A7D6-9D26-4253-B6EE-54942220B42BQ36952283-213CD2E1-E9CE-4EF9-8193-A49508F2A4EAQ37205817-A0365565-8334-46A1-B01B-790F1272F129Q37566850-4BFBB5DC-18D3-453B-A52A-0275F0E36B8BQ38260444-E4D0285E-6ACE-4EE3-8AE3-8EBE3187F4A9Q38663069-4A89B669-8868-4EC5-8B64-A721795B1C10Q38799845-0142311F-D5EC-4509-9FDE-6B7EBA04201DQ40234593-604576E9-B166-4C90-BA6B-4D115AE3D828Q40240418-A3174E86-5F40-4257-86F2-7A7C3FBF210BQ40968374-FF953336-A4D1-4CA1-930F-DBBC812D5BFEQ42329676-D53DA389-077D-443F-83CB-104C3D6F9D83Q47155582-766C4377-FFEF-42CC-A930-8C39B3B51836Q47736769-794DC4F0-886D-45EF-BA2E-24BBDEC89970Q48198158-CAD57BE3-3A2B-4D24-AEEE-677F23C3875BQ52803469-50A40598-F093-4B29-A36F-18DFE056B715Q57116328-935D28DA-D102-47E1-A299-C1524FF068D3Q57773818-877DDFBB-FFBC-4C15-A17D-3899AB33CF1F
P2860
A RAS renaissance: emerging targeted therapies for KRAS-mutated non-small cell lung cancer.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 03 June 2014
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
A RAS renaissance: emerging ta ...... ed non-small cell lung cancer.
@en
A RAS renaissance: emerging ta ...... ed non-small cell lung cancer.
@nl
type
label
A RAS renaissance: emerging ta ...... ed non-small cell lung cancer.
@en
A RAS renaissance: emerging ta ...... ed non-small cell lung cancer.
@nl
prefLabel
A RAS renaissance: emerging ta ...... ed non-small cell lung cancer.
@en
A RAS renaissance: emerging ta ...... ed non-small cell lung cancer.
@nl
P2860
P1476
A RAS renaissance: emerging ta ...... ed non-small cell lung cancer.
@en
P2093
Julie L Boyer
Neil Vasan
P2860
P304
P356
10.1158/1078-0432.CCR-13-1762
P407
P577
2014-06-03T00:00:00Z